Turn ASCO/EHA data into business-critical insights. 30 high-prescribing hem/oncs analyze 10 Chronic Lymphocytic Leukemia abstracts to help you prepare for what’s next. Take the guesswork out of understanding changes in prescribing behavior for: axicabtagene ciloleucel, epcoritamab, glofitamab, mosunetuzumab, naratuximab emtansine, pirtobrutinib (LOXO-305), polatuzumab vedotin, rituximab, and tisagenlecleucel among others. Get your 60+ slide report.

Chronic Lymphocytic Leukemia Report ASCO/EHA 2021

American Society of Clinical Oncology
, European Hematology Association

Virtual Meetings
ASCO: Jun 4 to Jun 8 / EHA: Jun 9 to Jun 17

Share: